ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization

PLEASANTON, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) — ProSomnus Sleep Technologies (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced record revenues for the quarter ended June 30, 2024 as it formally emerges from reorganization on August 5, 2024. “The past several months have clearly demonstrated the resilience of ProSomnus and the value … Read more

ProSomnus Announces Strong First Quarter 2024 Revenue Growth

PLEASANTON, Calif., May 16, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, today announced results for the first quarter ended March 31, 2024. “These exceptional results demonstrate ProSomnus’s value proposition, differentiation, and the quality of our people, providers, and processes,” said Len Liptak, Chief Executive Officer. “To … Read more

ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting

PLEASANTON, Calif., May 13, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at the 2024 American Academy of Dental Sleep Medicine Meeting in New Orleans. Data from three prospective clinical studies with a … Read more

Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices

PLEASANTON, Calif., May 09, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that four independent scientific abstracts accepted for the 2024 AADSM Annual Meeting contain scientific data utilizing ProSomnus precision devices, with one abstract winning the prestigious Clinical Excellence Award, and another featuring over 1,200 patients. … Read more

ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success

Announces Plan for $20 million in Aggregate New Financing to Support Daily Operations, Restructuring, Strategic Initiatives, and Advocacy Company Enters into Voluntary Chapter 11 Restructuring Process Which Will Take Company Private, Reduce Debt and Enable Execution of Key Initiatives Minimal Expected Operational Impact to Business, Company Will Continue Serving Customers and Delivering Products PLEASANTON, Calif., … Read more

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights “I am thrilled to announce another record revenue quarter and fiscal year for ProSomnus, as we establish the ProSomnus EVO® … Read more

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. … Read more

ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, … Read more

ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth quarter and fiscal year 2023 financial results and provide a business update before market open on Monday, March 18, 2024 at the 36th Annual ROTH Conference and via a live webcast. ProSomnus Chief … Read more

ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA

PLEASANTON, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today that the United States Food and Drug Administration (the “FDA”) has accepted, and is in the process of reviewing, the Company’s premarket notification for its ProSomnus® EVO® precision medical device for the treatment of patients with severe obstructive … Read more

Applicant Form

Thank you for your interest in ProSomnus career opportunities. Please choose your department of interest:

Resume Upload

By submitting this form, you may be contacted by our staff to verify information.

Brian Dow

Chief Financial Officer

Brian Dow is the Chief Financial Officer for ProSomnus® Sleep Technologies. Prior to joining ProSomnus in March of 2023, Mr. Dow served as Chief Financial Officer of Agendia N.V., a $60 million molecular diagnostics company, Senior Vice President and Chief Financial Officer of Pulse Biosciences (NASDAQ: PLSE), a development stage medical device company, and Principal Accounting Officer for Pacific Biosciences (NASDAQ: PACB), a commercial stage developer, manufacturer and provider of next generation sequencing instruments. Mr. Dow started his career as a manager with Ernst & Young.

Mr. Dow holds a B.S. in Management from the Georgia Institute of Technology and is recognized as a licensed certified public accountant by the Washington State Board of Accountancy.

Request Your Provider Portal Login Credentials

Please complete the form. A ProSomnus team member will reach out to you with your unique login credentials.

Request an Appointment